-

12:48:40 PM

BIIB Stock News

BIIB - Biogen Inc

03/16/23 6:30 AM

Nasdaq : BIIB

Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection

Biogen Inc. (Nasdaq: BIIB) today announced that the Court of Justice of the European Union decided in favor of Biogen, the European Medicines Agency (EMA), and the European Commission in their appeal of a General Court decision annulling the

RHEA-AI

neutral

03/14/23 7:30 AM

Nasdaq : BIIB

management

Biogen Appoints Chuck Triano as Head of Investor Relations

Biogen Inc. (NASDAQ: BIIB) today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations effective 10 April 2023. Mr. Triano will report to Michael McDonnell, Executive Vice President and Chief Financial

RHEA-AI

neutral

03/08/23 7:30 AM

Nasdaq : BIIB

management

Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors

Biogen Inc. (NASDAQ: BIIB) today announced that the Board of Directors has elected Caroline Dorsa as Chair of the Board of Directors, effective immediately following the Company’s 2023 Annual Meeting of Stockholders (the “Annual Meeting”),

RHEA-AI

very positive

03/08/23 6:30 AM

Nasdaq : SAGE, BIIB

Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone

Sage Therapeutics, Inc. and Biogen Inc. announced that the U.S. Food and Drug Administration notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the New Drug Application for zuranolone in the treatment of major depressive disorder and postpartum depression. This press release features...

RHEA-AI

neutral

03/05/23 6:30 PM

Nasdaq : BIIB

FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval Priority Review accelerates FDA review time with a Prescription Drug User Fee Act (PDUFA) target action on July 6, 2023 TOKYO and CAMBRIDGE, Mass.,

RHEA-AI

neutral

02/27/23 6:30 PM

Nasdaq : BIIB

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the Biologics License

RHEA-AI

very positive

02/06/23 6:30 AM

Nasdaq : BIIB

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

RHEA-AI

positive

01/29/23 6:30 PM

Nasdaq : BIIB

Lecanemab Receives Priority Review Status in Japan

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that an application for

RHEA-AI

very positive

01/26/23 6:30 PM

Nasdaq : BIIB

Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the European Medicines

RHEA-AI

very positive

01/15/23 7:30 PM

Nasdaq, OTC : BIIB, ESALY

EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN

Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril 1 antibody for the treatment of mild cognitive impairment due to Alzheimer's disease and mild AD dementia with confirmed...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

BIIB Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.biogen.com
CeoGeorge Scangos
Security nameBiogen Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees9610
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address225 Binney St
StateMassachusetts
CityCambridge
Zip02142-1031
CountryUS
Phone17814642000

About Biogen Inc

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.